Announcement of Potential Eligibility for Compensation Under Public Readiness and Emergency Preparedness Act Declaration and Filing Deadlines, 72740-72741 [07-6180]
Download as PDF
72740
Federal Register / Vol. 72, No. 245 / Friday, December 21, 2007 / Notices
mstockstill on PROD1PC66 with NOTICES
Therefore, FDA required that the terms
‘‘some types of cancer’’ or ‘‘some
cancers’’ be used in specifying the
disease for this health claim
relationship (id.). The antioxidant and
cancer and selenium and cancer
qualified health claims also contain
similar language, i.e., ‘‘certain forms of
cancer,’’ to be used in specifying the
disease. However, in other qualified
health claims for a substance and cancer
relationship (Refs. 6, 7, and 8), the
agency considered separate qualified
health claims for each type of cancer.
Cancer is a constellation of more than
100 different diseases, each
characterized by the uncontrolled
growth and spread of abnormal cells
(Ref. 9). Cancer is categorized into
different types of diseases based on the
organ and tissue sites (Ref. 10). Cancers
at different organ sites have different
risk factors, treatment modalities, and
mortality risk (Ref. 9). Both genetic and
environmental (including diet) risk
factors may affect the risk of different
types of cancers. Risk factors may
include a family history of a specific
type of cancer, cigarette smoking,
alcohol consumption, overweight and
obesity, exposure to ultraviolet or
ionizing radiation, exposure to cancercausing chemicals, and dietary factors.
The etiology, risk factors, diagnosis, and
treatment for each type of cancer are
unique (Refs. 11 and 12). Because each
form of cancer is a unique disease based
on organ site, risk factors, treatment
options, and mortality risk, FDA’s
current approach is to evaluate each
form of cancer individually in a health
claim or qualified health claim petition
to determine whether the scientific
evidence supports the potential
substance-disease relationship for any
type of cancer, each of which
constitutes a disease under
§ 101.14(a)(5).
The agency intends to consider, as
part of its reevaluation of the scientific
evidence for dietary fat, antioxidant,
and selenium and their association with
a reduced risk of cancer, claim language
to reflect specific types of cancer rather
than ‘‘certain forms of cancer’’ (or
similar language).
II. How to Submit Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individual may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
VerDate Aug<31>2005
18:37 Dec 20, 2007
Jkt 214001
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
Please note that in January 2008, the
FDA Web site is expected to transition
to the Federal Dockets Management
System (FDMS). FDMS is a
Government-wide, electronic docket
management system. After the transition
date, electronic submissions will be
accepted by FDA through the FDMS
only. When the exact date of the
transition to FDMS is known, FDA will
publish a Federal Register notice
announcing that date.
III. References
The following references have been
placed on display in the Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, rm. 1061, Rockville, MD 20852,
and may be seen by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday. (FDA has verified the
Web site addresses, but we are not
responsible for subsequent changes to
the Web sites after this document
publishes in the Federal Register.)
1. Balk E, Chung M, Chew P, Ip S, Raman
G, Kupelnick B, Tatsioni A, Sun Y, Wolk B,
DeVine D, Lau J. Effects of Soy on Health
Outcomes. Summary, Evidence Report/
Technology Assessment No. 126. (Prepared
by the Tufts-New England Medical Center
Evidence-based Practice Center under
Contract No. 290–02–0022.) AHRQ
Publication No. 05–E024–1. Rockville, MD:
Agency for Healthcare Research and Quality.
July 2005.
2. Institute of Medicine, National Academy
of Sciences. Dietary Referece Intakes for
energy, carbohydrate, fiber, fat, fatty acids,
cholesterol, protein and amino acids,
Chapter 11 page 808. National Academy
Press. Washington, D.C. 2005.
3. Antioxidant vitamins and risk of certain
cancers, April 1, 2003, https://www.cfsan.
fda.gov/~dms/ds-ltr34.html.
4. Selenium and certain cancers, February
21, 2003, Docket No. 2002P–0457 (formerly
Docket No. 02P–0457), https://www.cfsan.
fda.gov/~dms/ds-ltr35.html.
5. Huang HY, Caballero B, Chang S, Alberg
A, Semba R, Schneyer C, Wilson RF, Cheng
TY, Prokopowicz G, Barnes II GJ, Vassy J,
Bass EB. Multivitamin/Mineral Supplements
and Prevention of Chronic Disease. Evidence
Report/Technology Assessment No. 139.
(Prepared by The Johns Hopkins University
Evidence-based Practice Center under
Contract No. 290–02–0018). AHRQ
Publication No. 06–E012. Rockville, MD:
Agency for Healthcare Research and Quality.
May 2006.
6. Tomatoes and prostate, ovarian, gastric
and pancreatic cancers, November 8, 2005,
Docket No. 2004Q–0201, https://www.cfsan.
fda.gov/~dms/qhclyco.html.
7. Green tea and prostate and breast cancer
risk, June 30, 2005, Docket No. 2004Q–0083,
https://www.cfsan.fda.gov/~dms/qhcgtea.html.
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
8. Calcium and colon/rectal, breast and
prostate cancers and recurrent polyps,
October 12, 2005, Docket No. 2004Q–0097,
https://www.cfsan.fda.gov/~dms/
qhcca2.html.
9. American Cancer Society, Cancer Facts
and Figures, 2004.
10. National Cancer Institute, Dictionary of
Cancer Terms, https://www.cancer.gov/
Templates/db_alpha.aspx?CdrID=45333.
11. Hord NG, Fenton JI. Context is
everything: mining the normal and
preneoplastic microenvironment for insights
into the diet and cancer risk conundrum.
Molecular Nutrition and Food Research,
2007, 51:100–106.
12. Milner JA. Diet and Cancer: Facts and
Controversies. Nutrition and Cancer, 2006,
56:216–224.
Dated: December 6, 2007.
Barbara Schneeman,
Director, Office of Nutritional Products,
Labeling, and Dietary Supplements, Center
for Food Safety and Applied Nutrition.
[FR Doc. E7–24813 Filed 12–20–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Announcement of Potential Eligibility
for Compensation Under Public
Readiness and Emergency
Preparedness Act Declaration and
Filing Deadlines
Health Resources and Services
Administration (HRSA), HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This Notice provides
notification that individuals who have
been injured by pandemic, epidemic, or
security countermeasures identified in a
declaration issued by the Secretary
pursuant to section 319F–3(b) of the
Public Health Service Act (PHS Act) (42
U.S.C. 247d–6d) have one (1) year from
the time they receive the covered
countermeasure to file requests for
compensation for injuries directly
resulting from administration or use of
covered countermeasures under the
Public Readiness and Emergency
Preparedness Act (PREP Act).
DATES: This Notice is effective on
December 21, 2007.
FOR FURTHER INFORMATION CONTACT:
Healthcare Systems Bureau, Health
Resources and Services Administration,
Parklawn Building, Room 11C–26, 5600
Fishers Lane, Rockville, Maryland
20857; toll-free telephone number
1–888–496–0338. Electronic inquiries
should be sent via Tamara Overby at
toverby@hrsa.gov.
E:\FR\FM\21DEN1.SGM
21DEN1
Federal Register / Vol. 72, No. 245 / Friday, December 21, 2007 / Notices
The PREP
Act, which is a part of the ‘‘Department
of Defense, Emergency Supplemental
Appropriations to Address Hurricanes
in the Gulf of Mexico, and Pandemic
Influenza Act of 2006’’ (Pub. L. 109–
148), was enacted on December 30,
2005, and confers broad liability
protections on covered persons, as
defined in section 319F–3(i)(2) of the
PHS Act, and compensation to
individuals injured by the receipt of
covered countermeasures, as defined in
section 319F–3(i)(1) of the PHS Act, in
the event of designated public health
emergencies. A covered countermeasure
means: (A) A qualified pandemic or
epidemic product (as defined in section
319F–3(i)(7) of the PHS Act); (B) a
security countermeasure (as defined in
section 319F–2(c)(1)(B) of the PHS Act);
or (C) a drug (as such term is defined in
section 201(g)(1) of the Federal Food,
Drug and Cosmetic Act (21 U.S.C.
321(g)(1)), biological product (as such
term is defined by section 351(i) of this
Act), or device (as such term is defined
by section 201(h) of the Federal Food,
Drug and Cosmetic Act (21 U.S.C.
321(h)) that is authorized for emergency
use in accordance with section 564 of
the Federal Food, Drug and Cosmetic
Act.
Passed primarily to address the
pandemic influenza threat, the PREP
Act provides liability protections after a
Secretarial declaration of covered
countermeasures for any disease or
health condition that the Secretary
views as constituting a public health
emergency, either presently or in the
future. Liability protections cover the
manufacture, testing, development,
distribution, or use of the designated
covered countermeasure absent willful
misconduct as defined in section 319F–
3(c)(1) of the PHS Act. A Secretarial
declaration specifies the categories of
health threats or conditions for which
countermeasures are recommended, the
period liability protections are in effect,
the population of individuals protected,
and the geographic areas for which the
protections are in effect.
In addition to liability protections, the
PREP Act provides the Secretary the
authority, which was delegated by the
Secretary on November 8, 2006 to the
Administrator of the Health Resources
and Services Administration, to
compensate eligible individuals for
covered injuries from a covered
countermeasure.
The first Declaration under the PREP
Act was published in the Federal
Register on February 1, 2007 (72 FR
4710). It designated the pandemic
influenza A (H5N1) vaccine as a covered
countermeasure, with an effective time
mstockstill on PROD1PC66 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
18:37 Dec 20, 2007
Jkt 214001
period of December 1, 2006–February
28, 2010. As a result of this Declaration,
individuals injured by this vaccine can
file a request for compensation.
Individuals have one (1) year from the
time they receive the vaccine to apply
for compensation. Currently, no funds
have been appropriated to provide
compensation. However, all potential
claims must still be filed within the one
(1) year limit.
This Declaration specifies that the
following individuals with covered
injuries may be eligible to receive
compensation under the PREP Act: (1)
All persons who use a covered
countermeasure or to whom such a
covered countermeasure is administered
as an Investigational New Drug in a
human clinical trial conducted directly
by the Federal Government, or pursuant
to a contract, grant or cooperative
agreement with the Federal
Government; (2) all persons who use a
covered countermeasure or to whom
such a countermeasure is administered
in a pre-pandemic phase; and/or (3) all
persons who use a covered
countermeasure, or to whom such a
covered countermeasure is administered
in a pandemic phase. The Pre-Pandemic
Phase means the following stages, as
defined in the National Strategy for
Pandemic Influenza: Implementation
Plan (Homeland Security Council, May
2006): (0) New Domestic Animal
Outbreak in At-Risk Country; (1)
Suspected Human Outbreak Overseas;
(2) Confirmed Human Outbreak
Overseas; and (3) Widespread Human
Outbreaks in Multiple Locations
Overseas. The Pandemic Phase means
the following stages, as defined in the
National Strategy for Pandemic
Influenza: Implementation Plan
(Homeland Security Council, May
2006): (4) First Human Case in North
America; and (5) Spread Throughout
United States.
Eligible individuals may be
compensated for out-of-pocket medical
expenses, lost employment income, and
survivor death benefits. Reasonable and
necessary medical items and services
may be paid or reimbursed to treat a
covered countermeasure-related injury
of an eligible individual. The payments
or reimbursements for services or
benefits are secondary to other forms of
coverage. The individual may receive
compensation for loss of employment
income incurred as a result of the
covered countermeasure injury. The
amount of compensation is based on
income at the time of injury. Death
benefits may be paid to certain survivors
of covered countermeasures recipients
who have died as a direct result of the
covered countermeasure injury. Since
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
72741
HHS is payer of last resort, payments are
reduced by those of other third party
payers.
Interested parties may obtain request
packages that contain copies of all
necessary forms and instructions by
writing to the Healthcare Systems
Bureau, Health Resources and Services
Administration, Parklawn Building,
Room 11C–26, 5600 Fishers Lane,
Rockville, MD 20857, calling at 1–888–
496–0338, or downloading them from
the HRSA Web site at https://
www.hrsa.gov/countermeasurescomp.
Completed request packages must be
postmarked by the U.S. Postal Service,
a commercial carrier, or a private
courier service. HRSA will not accept
request packages electronically or by
hand-delivery. The postmark date is
used to determine whether the filing
deadline of one year from receipt of the
countermeasure has been met.
Paperwork Reduction Act of 1995
HRSA will submit to the Office of
Management and Budget (OMB) an
Information Collection Request (ICR) for
approval of the required forms.
Dated: December 18, 2007.
Elizabeth M. Duke,
Administrator.
[FR Doc. 07–6180 Filed 12–19–07; 1:36 pm]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Proposed Collection; Comment
Request; Cancer Care for Uninsured
Individuals: A Feasibility Study (NCI)
SUMMARY: In compliance with the
requirement of Section 3506(c)(2)(A) of
the Paperwork Reduction Act of 1995,
for opportunity for public comment on
proposed data collection projects, the
National Cancer Institute (NCI) of the
National Institutes of Health (NIH) will
publish periodic summaries of proposed
projects to be submitted to the Office of
Management and Budget (OMB) for
review and approval.
Proposed Collection
Title: Cancer Care For Uninsured
Individuals: A Feasibility Study. Type
of Information Collection Request:
NEW. Need and Use of Information
Collection: The purpose of this
information collection is to conduct a
pilot study to assess the feasibility of
obtaining health insurance information
for participants of the Prostate, Lung,
Colon and Ovarian (PLCO) Cancer
Screening Trial participants from health
E:\FR\FM\21DEN1.SGM
21DEN1
Agencies
[Federal Register Volume 72, Number 245 (Friday, December 21, 2007)]
[Notices]
[Pages 72740-72741]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-6180]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Announcement of Potential Eligibility for Compensation Under
Public Readiness and Emergency Preparedness Act Declaration and Filing
Deadlines
AGENCY: Health Resources and Services Administration (HRSA), HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This Notice provides notification that individuals who have
been injured by pandemic, epidemic, or security countermeasures
identified in a declaration issued by the Secretary pursuant to section
319F-3(b) of the Public Health Service Act (PHS Act) (42 U.S.C. 247d-
6d) have one (1) year from the time they receive the covered
countermeasure to file requests for compensation for injuries directly
resulting from administration or use of covered countermeasures under
the Public Readiness and Emergency Preparedness Act (PREP Act).
DATES: This Notice is effective on December 21, 2007.
FOR FURTHER INFORMATION CONTACT: Healthcare Systems Bureau, Health
Resources and Services Administration, Parklawn Building, Room 11C-26,
5600 Fishers Lane, Rockville, Maryland 20857; toll-free telephone
number 1-888-496-0338. Electronic inquiries should be sent via Tamara
Overby at toverby@hrsa.gov.
[[Page 72741]]
SUPPLEMENTARY INFORMATION: The PREP Act, which is a part of the
``Department of Defense, Emergency Supplemental Appropriations to
Address Hurricanes in the Gulf of Mexico, and Pandemic Influenza Act of
2006'' (Pub. L. 109-148), was enacted on December 30, 2005, and confers
broad liability protections on covered persons, as defined in section
319F-3(i)(2) of the PHS Act, and compensation to individuals injured by
the receipt of covered countermeasures, as defined in section 319F-
3(i)(1) of the PHS Act, in the event of designated public health
emergencies. A covered countermeasure means: (A) A qualified pandemic
or epidemic product (as defined in section 319F-3(i)(7) of the PHS
Act); (B) a security countermeasure (as defined in section 319F-
2(c)(1)(B) of the PHS Act); or (C) a drug (as such term is defined in
section 201(g)(1) of the Federal Food, Drug and Cosmetic Act (21 U.S.C.
321(g)(1)), biological product (as such term is defined by section
351(i) of this Act), or device (as such term is defined by section
201(h) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. 321(h))
that is authorized for emergency use in accordance with section 564 of
the Federal Food, Drug and Cosmetic Act.
Passed primarily to address the pandemic influenza threat, the PREP
Act provides liability protections after a Secretarial declaration of
covered countermeasures for any disease or health condition that the
Secretary views as constituting a public health emergency, either
presently or in the future. Liability protections cover the
manufacture, testing, development, distribution, or use of the
designated covered countermeasure absent willful misconduct as defined
in section 319F-3(c)(1) of the PHS Act. A Secretarial declaration
specifies the categories of health threats or conditions for which
countermeasures are recommended, the period liability protections are
in effect, the population of individuals protected, and the geographic
areas for which the protections are in effect.
In addition to liability protections, the PREP Act provides the
Secretary the authority, which was delegated by the Secretary on
November 8, 2006 to the Administrator of the Health Resources and
Services Administration, to compensate eligible individuals for covered
injuries from a covered countermeasure.
The first Declaration under the PREP Act was published in the
Federal Register on February 1, 2007 (72 FR 4710). It designated the
pandemic influenza A (H5N1) vaccine as a covered countermeasure, with
an effective time period of December 1, 2006-February 28, 2010. As a
result of this Declaration, individuals injured by this vaccine can
file a request for compensation. Individuals have one (1) year from the
time they receive the vaccine to apply for compensation. Currently, no
funds have been appropriated to provide compensation. However, all
potential claims must still be filed within the one (1) year limit.
This Declaration specifies that the following individuals with
covered injuries may be eligible to receive compensation under the PREP
Act: (1) All persons who use a covered countermeasure or to whom such a
covered countermeasure is administered as an Investigational New Drug
in a human clinical trial conducted directly by the Federal Government,
or pursuant to a contract, grant or cooperative agreement with the
Federal Government; (2) all persons who use a covered countermeasure or
to whom such a countermeasure is administered in a pre-pandemic phase;
and/or (3) all persons who use a covered countermeasure, or to whom
such a covered countermeasure is administered in a pandemic phase. The
Pre-Pandemic Phase means the following stages, as defined in the
National Strategy for Pandemic Influenza: Implementation Plan (Homeland
Security Council, May 2006): (0) New Domestic Animal Outbreak in At-
Risk Country; (1) Suspected Human Outbreak Overseas; (2) Confirmed
Human Outbreak Overseas; and (3) Widespread Human Outbreaks in Multiple
Locations Overseas. The Pandemic Phase means the following stages, as
defined in the National Strategy for Pandemic Influenza: Implementation
Plan (Homeland Security Council, May 2006): (4) First Human Case in
North America; and (5) Spread Throughout United States.
Eligible individuals may be compensated for out-of-pocket medical
expenses, lost employment income, and survivor death benefits.
Reasonable and necessary medical items and services may be paid or
reimbursed to treat a covered countermeasure-related injury of an
eligible individual. The payments or reimbursements for services or
benefits are secondary to other forms of coverage. The individual may
receive compensation for loss of employment income incurred as a result
of the covered countermeasure injury. The amount of compensation is
based on income at the time of injury. Death benefits may be paid to
certain survivors of covered countermeasures recipients who have died
as a direct result of the covered countermeasure injury. Since HHS is
payer of last resort, payments are reduced by those of other third
party payers.
Interested parties may obtain request packages that contain copies
of all necessary forms and instructions by writing to the Healthcare
Systems Bureau, Health Resources and Services Administration, Parklawn
Building, Room 11C-26, 5600 Fishers Lane, Rockville, MD 20857, calling
at 1-888-496-0338, or downloading them from the HRSA Web site at http:/
/www.hrsa.gov/countermeasurescomp.
Completed request packages must be postmarked by the U.S. Postal
Service, a commercial carrier, or a private courier service. HRSA will
not accept request packages electronically or by hand-delivery. The
postmark date is used to determine whether the filing deadline of one
year from receipt of the countermeasure has been met.
Paperwork Reduction Act of 1995
HRSA will submit to the Office of Management and Budget (OMB) an
Information Collection Request (ICR) for approval of the required
forms.
Dated: December 18, 2007.
Elizabeth M. Duke,
Administrator.
[FR Doc. 07-6180 Filed 12-19-07; 1:36 pm]
BILLING CODE 4165-15-P